Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8760046rdf:typepubmed:Citationlld:pubmed
pubmed-article:8760046lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:8760046lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:8760046lifeskim:mentionsumls-concept:C0072980lld:lifeskim
pubmed-article:8760046lifeskim:mentionsumls-concept:C1159690lld:lifeskim
pubmed-article:8760046lifeskim:mentionsumls-concept:C0729218lld:lifeskim
pubmed-article:8760046pubmed:issue1 Pt 1lld:pubmed
pubmed-article:8760046pubmed:dateCreated1996-12-3lld:pubmed
pubmed-article:8760046pubmed:abstractTextThe immunosuppressants cyclosporin A (CyA), FK-506, and rapamycin (RAP) have multiple actions on target cells that appear to be mediated by interaction of drug-binding protein complexes. Both FK-506 and CyA, but not RAP, inhibit the Ca2(+)-dependent phosphatase, calcineurin, and in so doing have been found to inhibit Na(+)-K(+)-ATPase activity in various nephron segments. Of interest, FK-506 and RAP, but not CyA, are bound by the steroid receptor-associated FK-506-binding heat shock protein of 56 kDa, HSP56. To determine the physiological effect of this interaction on a steroid-mediated phenomenon, the effect of these agents on steroid-mediated Na+ transport in A6 cells was investigated. Aldosterone stimulation of Na+ transport and Na(+)-K(+)-ATPase activity are significantly inhibited by prolonged incubation with FK-506 and RAP. Although CyA inhibits basal Na(+)-K(+)-ATPase activity, it has no effect on aldosterone-induced Na+ transport or the aldosterone-induced increase in Na(+)-K(+)-ATPase activity. FK-506 inhibits the aldosterone-induced synthesis of G alpha i-3 protein but has no effect on glucocorticoid receptor number as quantified by Western blotting. The results suggest that FK-506 and RAP inhibit steroid-mediated Na+ transport at some pretranslational site. The common interaction of these agents with the steroid receptor-associated HSP56 might account for these findings.lld:pubmed
pubmed-article:8760046pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:languageenglld:pubmed
pubmed-article:8760046pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:citationSubsetIMlld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8760046pubmed:statusMEDLINElld:pubmed
pubmed-article:8760046pubmed:monthJullld:pubmed
pubmed-article:8760046pubmed:issn0002-9513lld:pubmed
pubmed-article:8760046pubmed:authorpubmed-author:WestM EMElld:pubmed
pubmed-article:8760046pubmed:authorpubmed-author:JohnsonJ PJPlld:pubmed
pubmed-article:8760046pubmed:authorpubmed-author:PalevskyP MPMlld:pubmed
pubmed-article:8760046pubmed:authorpubmed-author:RokawM DMDlld:pubmed
pubmed-article:8760046pubmed:issnTypePrintlld:pubmed
pubmed-article:8760046pubmed:volume271lld:pubmed
pubmed-article:8760046pubmed:ownerNLMlld:pubmed
pubmed-article:8760046pubmed:authorsCompleteYlld:pubmed
pubmed-article:8760046pubmed:paginationC194-202lld:pubmed
pubmed-article:8760046pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:meshHeadingpubmed-meshheading:8760046-...lld:pubmed
pubmed-article:8760046pubmed:year1996lld:pubmed
pubmed-article:8760046pubmed:articleTitleFK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells.lld:pubmed
pubmed-article:8760046pubmed:affiliationLaboratory of Epithelial Cell Biology, University of Pittsburg Medical Center, Pennsylvania, USA.lld:pubmed
pubmed-article:8760046pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8760046pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8760046pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed